search
Back to results

Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia

Primary Purpose

Peripheral Arterial Disease, Critical Limb Ischaemia

Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Revitive IX
Sponsored by
Imperial College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease focused on measuring Peripheral Vascular Disease, Critical Limb Ischaemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Willing, able, and committed to participate in the procedures for the full length of the study.
  • All ethnic groups, male or female above the age of 18 years.
  • Diagnosis of non-reconstructable arterial disease and critical limb ischaemia (with a minimum of duplex ultrasound and an MDT discussion to have reached this diagnosis)
  • Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the study device.
  • Blood pressure currently under moderate control (< 160/100mmHg)
  • History of uncomplicated cardiovascular events beyond 3 months.
  • No current foot ulceration

Exclusion Criteria:

Patients meeting any of the following criteria are to be excluded:

  • Has an unstable condition (eg, psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the study protocol.
  • Has any metal implants
  • Pregnant
  • Has peripheral neuropathy
  • Has a cardiac pacemaker or defibrillator device
  • Has recent lower limb injury or lower back pain
  • Has current foot ulceration or other skin ulcers
  • Has foot deformities
  • Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study
  • Ankle-Brachial Pressure Index >0.9

Sites / Locations

  • Imperial College London - Charing Cross Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intervention

Arm Description

Revitive IX Neuromuscular Electrical Stimulation Device

Outcomes

Primary Outcome Measures

Pain Score
Change in pain score with device use over a 6 week period. Measure by a visual analogue scale of pain with 0 = no pain and 10 = maximum pain

Secondary Outcome Measures

Major amputation rate
Identify if and number of major amputations carried out during study period.
Flow rate in Femoral Artery
Duplex ultrasound guided measurement of femoral artery flow rate whilst using the device on day 1 and then 6 weeks later during follow up visit.
Femoral artery diameter
Duplex ultrasound guided measurement of femoral artery diameter whilst using the device on day 1 and then 6 weeks later during follow up visit.
Disease specific questionnaire - VascuQoL
Change of disease specific Quality of Life (QoL) measure from baseline to 6 weeks.
Short Form - 36 (SF-36)
Change ofSF-36 Quality of Life (QoL) score from Day 1 to 6 weeks.
EuroQol - EQ5D
Change of EQ5D Quality of Life (QoL) score from Day 1 to 6 weeks.
Patient compliance using diary of device use
Check the frequency of device use over the 6 week study period.

Full Information

First Posted
December 1, 2015
Last Updated
June 4, 2019
Sponsor
Imperial College London
search

1. Study Identification

Unique Protocol Identification Number
NCT02634138
Brief Title
Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia
Official Title
Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia
Study Type
Interventional

2. Study Status

Record Verification Date
June 2019
Overall Recruitment Status
Terminated
Why Stopped
Halted prematurely
Study Start Date
November 2015 (undefined)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
October 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will assess the benefit of a neuromuscular electrical stimulation device in patients suffering from symptoms and effects of critical limb ischaemia.
Detailed Description
The circulation of blood around the body is dependent on effective pumping of the heart. Patients with arterial insufficiency are known to have poor circulation in their lower legs and feet leading to various complications such as swelling and painful legs and reduced healing of injuries. Peripheral arterial disease (PAD) can be defined as a narrowing of the arteries reducing blood flow. It is most commonly due to atherosclerosis, and has associations with heart disease, stroke, and diabetes. Its incidence is estimated at 7-14% in the general population, increasing with age to about 20% in the over-seventies. It is associated with effects on mobility, skin condition and quality of life. Symptoms include pain in the legs on walking (intermittent claudication), pain at rest (particularly at night), gangrene, and limb loss. Management of PAD is based on encouraging exercise, and modification of risk factors such as smoking, high blood pressure, high cholesterol and diabetes. In patients with PAD, exercise tolerance is often limited. Severe symptoms and disease can be treated via such as balloon angioplasty, stenting or surgical bypass, but these procedures have risk. There also remains a percentage of patients who are not suitable for revascularisation, and have only a few options such as amputation available to them. Some trials have shown that increasing the blood flow in the legs over time using medical devices (intermittent pneumatic compression, muscle stimulators), in addition to maximal medical and surgical therapy, can increase claudication distance, absolute walking distance, decrease rest pain, and reduce amputation rates. In the investigators unit it has become apparent that there are an increasing number of medical devices available for circulatory support, either as an inpatient, out-patient, or a member of the general public. The supporting evidence for these is variable in scientific and clinical content or relevance, and requires clinical trials to evaluate further. Revitive activates the pumping action of leg muscles by providing electrical muscle stimulation to cause foot muscle contraction and relaxation which squeezes blood back towards the heart, improving circulation. The investigators wish to evaluate whether NMES using this device has the same beneficial effects in patients with critical limb ischaemia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease, Critical Limb Ischaemia
Keywords
Peripheral Vascular Disease, Critical Limb Ischaemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Revitive IX Neuromuscular Electrical Stimulation Device
Intervention Type
Device
Intervention Name(s)
Revitive IX
Intervention Description
A foot plate Neuromuscular Electrical Stimulation Device
Primary Outcome Measure Information:
Title
Pain Score
Description
Change in pain score with device use over a 6 week period. Measure by a visual analogue scale of pain with 0 = no pain and 10 = maximum pain
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Major amputation rate
Description
Identify if and number of major amputations carried out during study period.
Time Frame
6 weeks
Title
Flow rate in Femoral Artery
Description
Duplex ultrasound guided measurement of femoral artery flow rate whilst using the device on day 1 and then 6 weeks later during follow up visit.
Time Frame
Day 1 then at 6 weeks
Title
Femoral artery diameter
Description
Duplex ultrasound guided measurement of femoral artery diameter whilst using the device on day 1 and then 6 weeks later during follow up visit.
Time Frame
Day 1 and at 6 weeks
Title
Disease specific questionnaire - VascuQoL
Description
Change of disease specific Quality of Life (QoL) measure from baseline to 6 weeks.
Time Frame
Day 1 and at 6 weeks
Title
Short Form - 36 (SF-36)
Description
Change ofSF-36 Quality of Life (QoL) score from Day 1 to 6 weeks.
Time Frame
Day 1 and at 6 weeks
Title
EuroQol - EQ5D
Description
Change of EQ5D Quality of Life (QoL) score from Day 1 to 6 weeks.
Time Frame
Day 1 and at 6 weeks
Title
Patient compliance using diary of device use
Description
Check the frequency of device use over the 6 week study period.
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Willing, able, and committed to participate in the procedures for the full length of the study. All ethnic groups, male or female above the age of 18 years. Diagnosis of non-reconstructable arterial disease and critical limb ischaemia (with a minimum of duplex ultrasound and an MDT discussion to have reached this diagnosis) Be of non-childbearing potential; OR using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the study device. Blood pressure currently under moderate control (< 160/100mmHg) History of uncomplicated cardiovascular events beyond 3 months. No current foot ulceration Exclusion Criteria: Patients meeting any of the following criteria are to be excluded: Has an unstable condition (eg, psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the study protocol. Has any metal implants Pregnant Has peripheral neuropathy Has a cardiac pacemaker or defibrillator device Has recent lower limb injury or lower back pain Has current foot ulceration or other skin ulcers Has foot deformities Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study Ankle-Brachial Pressure Index >0.9
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alun H Davies, BA BMChB MA
Organizational Affiliation
Imperial College London
Official's Role
Study Chair
Facility Information:
Facility Name
Imperial College London - Charing Cross Hospital
City
London
ZIP/Postal Code
W6 8RF
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia

We'll reach out to this number within 24 hrs